Jasper Therapeutics (JSPR) Other Non-Current Liabilities (2019 - 2025)
Jasper Therapeutics (JSPR) posted quarterly Other Non-Current Liabilities of $2.3 million for Q4 2025, little changed year-over-year from $2.3 million in Q4 2024, and down 89.82% quarter-over-quarter from $22.6 million in Q3 2025.
Jasper Therapeutics (JSPR) Other Non-Current Liabilities (2019 - 2025) Analysis & Trends
Jasper Therapeutics' Other Non-Current Liabilities history runs 7 years deep, the most recent figure standing at $2.3 million for Q4 2025.
- In Q4 2025, Other Non-Current Liabilities changed 0.0% year-over-year to $2.3 million; the TTM figure through Dec 2025 stood at $2.3 million (changed 0.0% YoY), while the FY2025 annual figure was $2.3 million, changed 0.0% from the prior year.
- Other Non-Current Liabilities for Q4 2025 stood at $2.3 million, down from $22.6 million in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $22.6 million in Q3 2025, with the low at $18000.0 in Q4 2022.
- The 5-year median for Other Non-Current Liabilities is $712500.0 (2021), against an average of $2.9 million.
- The sharpest annual moves came in 2023 and 2024: Other Non-Current Liabilities surged 12477.78% in 2023, then tumbled 97.44% in 2024.
- Jasper Therapeutics' Other Non-Current Liabilities stood at $643000.0 in 2021, then plunged by 97.2% to $18000.0 in 2022, then soared by 12477.78% to $2.3 million in 2023, then advanced by 1.59% to $2.3 million in 2024, then changed by 0.0% to $2.3 million in 2025.
- Business Quant data shows JSPR's Other Non-Current Liabilities at $2.3 million in Q4 2025, $22.6 million in Q3 2025, and $2.3 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.41 Bn | 131.56 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.14 Bn | 78.15 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.52 Bn | 60.34 Bn | 1.37 Bn |
| 4 | Moderna | 58.21 Bn | 53.07 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.15 Bn | 37.05 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.62 Bn | 28.31 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.95 Bn | 9.56 Bn | 668.28 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.30 Bn | 26.46 Bn | - |
| 10 | Jasper Therapeutics | 20.09 Mn | 20.09 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.30 Mn |
| Sep 30, 2025 | 22.59 Mn |
| Jun 30, 2025 | 2.26 Mn |
| Mar 31, 2025 | 2.26 Mn |
| Dec 31, 2024 | 2.30 Mn |
| Sep 30, 2024 | 2.26 Mn |
| Jun 30, 2024 | 20,000.00 |
| Mar 31, 2024 | 20,000.00 |
| Dec 31, 2023 | 2.26 Mn |
| Sep 30, 2023 | 28,000.00 |
| Jun 30, 2023 | 362,000.00 |
| Mar 31, 2023 | 782,000.00 |
| Dec 31, 2022 | 18,000.00 |
| Sep 30, 2022 | 103,000.00 |
| Jun 30, 2022 | 525,000.00 |
| Mar 31, 2022 | 600,000.00 |
| Dec 31, 2021 | 643,000.00 |
| Sep 30, 2021 | 600,000.00 |
| Jun 30, 2021 | 10.43 Mn |
| Mar 31, 2021 | 7.42 Mn |